[
  {
    "ts": null,
    "headline": "WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?",
    "summary": "West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.",
    "url": "https://finnhub.io/api/news?id=f0793bc430dccc0409f9d09ad4a1868230f09f4e0ca09fdc32131c17a90dd644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753200660,
      "headline": "WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?",
      "id": 136033722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.",
      "url": "https://finnhub.io/api/news?id=f0793bc430dccc0409f9d09ad4a1868230f09f4e0ca09fdc32131c17a90dd644"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks",
    "summary": "West Pharmaceutical Services Inc. (NYSE:WST) is one of the most oversold S&P 500 stocks so far in 2025. On June 24, Barclays analyst Luke Sergott began coverage on West Pharmaceutical Services (WST) with an Equal Weight rating and a price target of $245. In his view, while the company maintains a solid foothold in its core […]",
    "url": "https://finnhub.io/api/news?id=b1397e6552478a3d007a5ddf475c32cb2eed5441eead0be66e3233586734b691",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753193324,
      "headline": "Barclays Cautious on West Pharma (WST) on Non-Core Weakness and Injectable Disruption Risks",
      "id": 136032314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services Inc. (NYSE:WST) is one of the most oversold S&P 500 stocks so far in 2025. On June 24, Barclays analyst Luke Sergott began coverage on West Pharmaceutical Services (WST) with an Equal Weight rating and a price target of $245. In his view, while the company maintains a solid foothold in its core […]",
      "url": "https://finnhub.io/api/news?id=b1397e6552478a3d007a5ddf475c32cb2eed5441eead0be66e3233586734b691"
    }
  }
]